Pfizer Inc.’s Prevnar 13 is the first pneumococcal vaccine to be approved by FDA for use in children and adolescents aged six to 17 years. But the expanded indication is not likely to have a major impact on Pfizer’s vaccine revenues.
Asked if the company was distributing more doses of Prevnar 13 to cover this population, a Pfizer spokesperson said the incidence of pneumococcal disease is low in the six-to-17-year age group, although there is an increased risk for children with certain chronic